Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Andersen, Mette K
Johannsson, Johann H
MetadataShow full item record
CitationBr. J. Haematol. 2008, 140(6):665-72
AbstractThe prognostic impact of t(12;21)(p13;q22) [ETV6/RUNX1 fusion] in paediatric acute lymphoblastic leukaemia (ALL) has been extensively debated, particularly with regard to the frequency of late relapses and appropriate treatment regimens. We have retrospectively collected 679 ALLs with known ETV6/RUNX1 status, as ascertained by fluorescence in situ hybridization or reverse-transcription polymerase chain reaction, treated according to the Nordic Society of Paediatric Haematology and Oncology -ALL-1992 protocol. The assigned risk groups/treatment modalities for the 171 (25%) patients with t(12;21)-positive ALLs were 74 (43%) standard risk, 71 (42%) intermediate risk and 26 (15%) high risk. The 5- and 10-year event-free survival (EFS) of the 171 patients was 80% and 75% respectively, with no significant differences among the three risk groups. Most of the relapses occurred in boys and were late, with almost 50% of all relapses occurring > or = 5 years after diagnosis. Of all relapses after 6 years, 80% occurred in the t(12;21)-positive group. The overall survival was 94% at 5 years and 88% at 10 years; thus, the treatment of patients in second or later remission is usually successful. As yet, there is no reliable plateau in the EFS curve, a fact that raises the question as to when the prognostic ramifications of ALLs harbouring ETV6/RUNX1 should be evaluated.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia.
- Authors: Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Calasanz MJ, Garate L, San Jose-Eneriz E, Cordeu L, Prosper F, Heiniger A, Torres A
- Issue date: 2006 Aug 15
- Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes.
- Authors: Peter A, Heiden T, Taube T, Körner G, Seeger K
- Issue date: 2009 Nov
- High incidence of the ETV6/RUNX1 fusion gene in paediatric precursor B-cell acute lymphoblastic leukaemias with trisomy 21 as the sole cytogenetic change: a Nordic series of cases diagnosed 1989-2005.
- Authors: Karrman K, Forestier E, Andersen MK, Autio K, Borgström G, Heim S, Heinonen K, Hovland R, Kerndrup G, Johansson B, Nordic Society of Paediatric Haematology and Oncology (NOPHO) and the NOPHO Leukaemia Cytogenetic Study Group (NLCSG).
- Issue date: 2006 Nov
- Presenting features of 201 children with acute lymphoblastic leukemia: comparison according to presence or absence of ETV6/RUNX1 rearrangement.
- Authors: Alvarez Y, Caballín MR, Gaitán S, Pérez A, Bastida P, Ortega JJ, Cervera J, Verdeguer A, Tasso M, Aventín A, Badell I, Guitart M, Melo M, Granada I, Javier G, Dastugue N, Robert A, Coll MD
- Issue date: 2007 Sep
- ETV6/RUNX1 fusion lacking prognostic effect in pediatric patients with acute lymphoblastic leukemia.
- Authors: Zen PR, Capra ME, Silla LM, Loss JF, Fernandes MS, Jacques SM, Paskulin GA
- Issue date: 2009 Jan 15